Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01940809
Title Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Dabrafenib + Ipilimumab

Ipilimumab + Nivolumab + Trametinib

Dabrafenib + Ipilimumab + Trametinib

Ipilimumab + Trametinib

Dabrafenib + Ipilimumab + Nivolumab

Ipilimumab

Ipilimumab + Nivolumab

Dabrafenib + Ipilimumab + Nivolumab + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST